From: Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Author, year [reference] | Ages (y) | A/P | Dropouts (A/P) | Allergen | Duration | Dose and administration | Disease | Manu-facturer | Main positive results | Negative results |
---|---|---|---|---|---|---|---|---|---|---|
Horak, 2009 [43] | 18-50 | 45/44 | 3/4 | Grass | 4 mo | 20 mcg | RC | STA | Significant reduction in RC score in Vienna challenge chamber at 4 mo in SLIT vs baseline and vs placebo (the reduction vs placebo was 29%) | Nasal airflow |
Phl p 5/day | Weight of secretions | |||||||||
Tablets | Basophil activation | |||||||||
Increased IgE and IgG4 | ||||||||||
Skoner, 2010 [46] | 18-50 | 39 med | 4 | Ragweed | 6 mo | 4.8 or 48 mcg | RC | GRE | Combined symptoms+drugs and drug score versus placebo | Nasal challenge, IgE |
36 high | 5 | Amb a 1/day | Symptom score | |||||||
40 plac | 3 | Metered pump | during peak season | |||||||
Cortellini, 2010 [42] | 16-44 | 15/12 | 0/1 | Alternaria | 10 mo | 60 mcg Alt a 1 cumul. 6 mcg/mo | RCA | ANA | Significant reduction in combined score (-38% versus placebo). | Specifcic IgE and IgG4 |
Drops | Significant reduction in skin reactivity | |||||||||
Panizo, 2010 [45] | 18-65 | 52/26 | 2/1 | Grass | 5 mo | 25 mcg Phl p 5/day Tablets | RC | ALK | Increase in IgE, IgG4, and IgE blocking activity only in active | |
Yonekura, 2010 [48] | 7-15 | 20/11 | 1/2 | Mite | 1 y | 0.5 mcg Der f 1 once a week | RC | TOR | Significant decrease in symptoms and combined score in wk 0–3 and 37–40 only in SLIT | Medication score |
Blaiss, 2011 [40] | 5-17 | 349/358 | 33/30 | Grass | 6 mo | 450 g Phl p 5/mo | RC | STA | Significant reduction in combined score (-26%) versus placebo. Quality of Life 38% improvement vs placebo | Asthma symptoms |
Nelson, 2011 [44] | 18-63 | 213/225 | 33/33 | Grass | 10 mo | 450 mcg Phl p 5/mo Tablets | RCA | STA | Significant reduction in combined score (-20%and medication score (-20%) versus placebo | Daily medication score |
Bush, 2011 [41] | 18-50 | High 10 | 2 | Mite | 18 mo | 70 or 1 mcg | RA | GRE | Significant reduction in specific bronchial reactivity | Symptoms and medication scores |
Low 10 | 3 | (Der f) | Der f 1 per dose. | |||||||
Pla 11 | 5 | Drops | ||||||||
Increase in IgG4 | ||||||||||
Stelmach, 2012 [47] | 6-18 | Cont 20 | 3 | Grass | 2 y | Cumulative 7.3 and 3.6 mcg Phl p 5. Drops | RCA | ALK | Significant improvement in drugs +symptoms with both continuous and precoseasonal regimen. Reduction in FeNO | Symptom score |
Prec 20 | 1 | Medication score | ||||||||
Pla 20 | 2 | Pulmonary function | ||||||||
de Bot, 2012 [53] | 6-18 | 126/125 | 15/17 | Mite | 2 y | 4.06 mcg | RC | ART | Symptom score | |
Der p 1/week | QoL | |||||||||
Drops | Medication score | |||||||||
Well days | ||||||||||
Ahmadiasfshar 2012 [49] | 5-18 | 12/12 | 2/2 | Grass | 6 mo | Cumulative: about 6,000 IR Spray | RC | STA | Significant improvement in symptom and medication scores | |
Reduction of skin wheal diameter | ||||||||||
Wahn, 2012 [54] | 4-12 | 158/49 | 26/2 | Grass | 8 mo | Cumulative: 7.2–8.4 mg group 5 | RC | ALL | Significant reduction versus placebo in combined symptom/medication and individual scores | |
Drops | ||||||||||
Cox, 2012 [51] | 18-65 | 233/240 | 26/17 | Grass | 6 mo | Cumulative: approx 3.6 mg group 5 allergen. | RC | STA | Significant reduction of combined symptom + medication score (-28% versus placebo) and overall quality of life | Itchy nose symptom score versus placebo |
Tablets | ||||||||||
Bozek, 2013 [50] | 60-75 | 51/57 | 7/9 | Mite | 3 y | NS | RC | STA | Total nasal scores decreased by 44% from baseline in SLIT and by 6% in placebo. | Symptoms after specific nasal provocation versus placebo |
Medication score decreased 35% from baseline in SLIT group. | ||||||||||
Wang, 2013 [55] | 4-65 | 60/60 | 12/23 | Mite | 6 mo | NS | RC | ZHE | Significant decrease in each individual rhinitis symptom versus placebo starting from week 14. | No change versus placebo in medication intake |
Nolte, 2013 [18] | 18-50 | High 187 | 142 | Ragweed | 1 y | 6 or 12 mcg | RCA | MSD | Significant decrease in combined symptom + medication score for both active groups VS placebo (21% and 27%) | |
Low 190 | overall | Amb a 1 daily | ||||||||
Pla 188 | Tablets | |||||||||
Creticos, 2013 [52] | 18-50 | Low 197 | 40 | Ragweed | 1 y | Cumulative dose | RCA | MSD | Only the high dose decreased daily symptom, medication, and combined scores during peak pollen season and whole season versus placebo. | Low dose overall less effective than the 2 other doses on symptoms/medications in peak pollen and whole season |
Med 195 | 43 | 4.38 mg Amb a 1 | ||||||||
High 194 | 57 | Tablets | ||||||||
Pla 198 | 38 |